Drug Profile
Research programme: HIV ribozyme therapy - Viratis
Latest Information Update: 11 May 2010
Price :
$50
*
At a glance
- Originator Viratis
- Class
- Mechanism of Action CCR5 receptor antagonists; CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 06 Jun 2007 Preclinical trials in HIV infections in United Kingdom (IV)